CORX Financials 07/16/2014 07:05:43
Cortex Pharmaceuticals, Inc.
Period Ending Dec 31, 2011 Dec 31, 2010
Total Revenue 3,115 10,474
Cost of Revenue - -
Gross Profit 3,115 10,474
Operating Expenses
Research and Development 2,188 3,739
Sales, General and Admin. 3,189 4,553
Non-Recurring Items - -
Other - -
Operating Income (2,262) 2,182
Income From Continuing Operations
Add'l Income/Expense Items - -
Earnings Before Interest and Tax (2,255) 1,629
Interest Expense - -
Earnings Before Tax (2,255) 1,629
Income Tax - -
Minority Interest - -
Equity Earnings Unconsolidated Subsidiary - -
Net Income Cont. Operations (2,255) 1,629
Non Recurring Events
Discontinued Operations - -
Extraordinary Items - -
Effect of Accounting Changes - -
Other Items - -
Net Income (2,255) 1,629
Preferred Stock and Other Adjustments - -
Net Income Applicable to Common Shareholders (2,255) 1,629
Cortex Pharmaceuticals, Inc.
Period Ending Dec 31, 2011 Dec 31, 2010
Total Revenue 3,115 10,474
Cost of Revenue - -
Gross Profit 3,115 10,474
Operating Expenses
Research and Development 2,188 3,739
Sales, General and Admin. 3,189 4,553
Non-Recurring Items - -
Other - -
Operating Income (2,262) 2,182
Income From Continuing Operations
Add'l Income/Expense Items - -
Earnings Before Interest and Tax (2,255) 1,629
Interest Expense - -
Earnings Before Tax (2,255) 1,629
Income Tax - -
Minority Interest - -
Equity Earnings Unconsolidated Subsidiary - -
Net Income Cont. Operations (2,255) 1,629
Non Recurring Events
Discontinued Operations - -
Extraordinary Items - -
Effect of Accounting Changes - -
Other Items - -
Net Income (2,255) 1,629
Preferred Stock and Other Adjustments - -
Net Income Applicable to Common Shareholders (2,255) 1,629
